Saturday, March 15, 2025 | 12:46 PM ISTहिंदी में पढें
Business Standard
Notification Icon
userprofile IconSearch

Aurobindo gains 5% on govt nod for promotion of manufacturing bulk drugs

Aurobindo Pharma (through Lyfius Pharma) has received government approval for setting up plants for production of Penicillin-G and 7-ACA, under the PLI scheme

pharmacy, drugs, medicine, pharma companies, pharmaceuticals, vaccine, coronavirus, covid, testing
Premium

Representative image

SI Reporter Mumbai
Shares of Aurobindo Pharma rose 5 per cent to Rs 966 in intra-day trade on the BSE on Monday, thus gaining 7 per cent in the past two trading days, on report that the government has given the company approval under the Production Linked Incentive (PLI) scheme for promotion of domestic manufacturing of critical bulk drugs. The PLI scheme aims at promotion of manufacturing of critical key starting materials (KSMs)/drug intermediates and APIs in the country.

According to a report by Press Trust of India, Aurobindo Pharma (through Lyfius Pharma) received government approval for setting up plants for production

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in